The regulation of mTOR/AMPK-dependent metabolic pathways and/or MCT1 lactate transporter activity protects DCs from the deleterious effects of tumor-derived metabolic byproducts, thus enabling robust anti-tumor immune responses (56). Here, MTOR is linked to neoplasm.